Coherus Oncology, Inc. (CHRS) NASDAQ
1.58
+0.105(+7.14%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
1.58
+0.105(+7.14%)
Currency In USD
| Previous Close | 1.47 |
| Open | 1.5 |
| Day High | 1.59 |
| Day Low | 1.5 |
| 52-Week High | 2.62 |
| 52-Week Low | 0.71 |
| Volume | 832,086 |
| Average Volume | 1.28M |
| Market Cap | 192.8M |
| PE | -1.11 |
| EPS | -1.42 |
| Moving Average 50 Days | 1.71 |
| Moving Average 200 Days | 1.59 |
| Change | 0.11 |
Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026
GlobeNewswire Inc.
Mar 02, 2026 2:30 PM GMT
REDWOOD CITY, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its full year and fourth quarter 2025 financial results will be released after market close on Monday, March 9, 2026. Starting at 4
Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock
GlobeNewswire Inc.
Feb 17, 2026 9:11 PM GMT
–The Offering was led by healthcare-dedicated investors including Janus Henderson Investors, HBM Healthcare Investments and Samsara BioCapital– REDWOOD CITY, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (“Coherus” or the “Compan
Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock
GlobeNewswire Inc.
Feb 13, 2026 2:18 AM GMT
REDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (“Coherus” or the “Company”) (NASDAQ: CHRS), today announced the pricing of an underwritten public offering of 28,600,000 shares of the Company’s common stock (the “Offe